Implementation of an Outpatient HD-MTX Initiative.

Introduction: Methotrexate (MTX) a folate antagonist is often given in high doses (≥500 mg/m) to treat a variety of disease processes. While inpatient administration has been the norm, outpatient administration, has been shown to be safe, effective, and patient centered. Here in we describe development of an outpatient HDMTX protocol and our initial experience.